New publication using Attana Technology for developing synthetic antibodies

Report this content

The detection of proteins and peptides is necessary in many clinical diagnostics applications and has been of high importance during the pandemic. Detection using antibodies is well established due to their high specificities and selectivity. However, they have limited chemical- and physical stabilities concerning shelf lives and transport. This paper describes the development of synthetic antibodies with high stability, and the comparable specificity and selectivity for commercially available antibodies.

The team of Prof. Nicholls at the Linnaeus University describes how they have developed polymer nanoparticles against Oxytocin. They characterized the nanoparticles with light scattering, scanning- and transmission electron microscopy, and X-ray photoelectron spectroscopy. To determine the specificity and selectivity, they used Attana´s Quartz Crystal Microbalance (QCM) technology, the Attana Cell™ 200 instrument and displayed an affinity of 0.3nM which could be compared to commercial polyclonal antibodies displaying an affinity of 0.02–0.2nM.

The work was partly financed by The Swedish Knowledge Foundation (Grant Nos: 20190114, 20170059)

Read the full publication here:

For more information, please contact:

Teodor Aastrup, CEO
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit or contact





Documents & Links